Handelsavisen
prelaunch
Companies Healthcare 300595.SZ
30
300595.SZ Shenzhen Stock Exchange Medical Equipment, Supplies & Distribution

Autek China Inc

¥12,21
Open in Charts → Attach watcher ⌖
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
1,17 %
Op margin
34,9 %
ROE
9,8 %
Net margin
25,8 %
Debt / equity
0,06
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Autek China Inc provides medical equipment, supplies, and distribution services within the healthcare sector.

Business. Autek China Inc (300595.SZ) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, including capital equipment and consumables. Headquartered in China, the company is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
HOLD6 analysts
2 buy3 hold1 sell
Avg 12m price target16,28

Analyst recommendations

6 analysts · consensus Hold
Buy2
Hold3
Sell1
12-month price target
16,28
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
6 analysts · indicative
Ownership
not yet wired
Profitability
9,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 300595.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 300595.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Autek China Inc (300595.SZ) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, including capital equipment and consumables. Headquartered in China, the company is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    Autek China Inc maintains a strong liquidity position with a current ratio of 5.77, indicating a robust ability to meet short-term obligations. The company's liquidity_fpt score suggests a medium liquidity risk, which is consistent with its operating cash flow of 730,078,200 CNY and free cash flow of 327,817,940 CNY. However, the company has a net cash position that is negative after subtracting total debt, which may pose a liquidity risk in the medium term.

    In terms of profitability, Autek China Inc demonstrates a return on equity (ROE) of 9.76% and a return on assets (ROA) of 7.66%, both of which are above the industry median for medical equipment and supplies firms. The company's operating income of 649,222,350 CNY and net income of 479,524,590 CNY reflect a healthy margin structure, supported by a gross profit of 1,343,291,200 CNY.

    The company's geographic and segment exposure is not explicitly detailed in the available data, but its revenue concentration is likely within the domestic Chinese market, given its listing on the Shenzhen Stock Exchange and the absence of international revenue breakdowns. This may limit its exposure to global healthcare trends and diversify its risk profile.

    Autek China Inc's growth trajectory is not explicitly outlined in the available data, but its revenue of 1,861,147,150 CNY and consistent operating cash flow suggest a stable business model. Analysts have assigned a mean price target of 16.28 CNY and a median price target of 17.75 CNY, with a mean recommendation of 2.83, indicating a generally positive outlook.

    The company's risk profile is characterized by a low dilution risk, with no significant dilution sources identified in the available data. However, the negative net cash position after subtracting total debt may indicate a need for capital management or refinancing in the near term. The company's debt-to-equity ratio of 0.06 suggests a conservative capital structure, with long-term debt of 300,961,220 CNY and total equity of 4,911,934,620 CNY.

    Recent events and filings have not been explicitly detailed in the available data, but the company's consistent operating cash flow and free cash flow suggest a stable financial position. The absence of recent dilutive events or significant capital expenditures may indicate a focus on maintaining financial stability.

    Key takeaways
    • Autek China Inc maintains a strong liquidity position with a current ratio of 5.77.
    • The company's ROE of 9.76% and ROA of 7.66% are above industry medians, indicating strong profitability.
    • The company's capital structure is conservative, with a debt-to-equity ratio of 0.06.
    • Analysts have assigned a generally positive outlook, with a mean price target of 16.28 CNY.
    • The company's net cash position is negative after subtracting total debt, which may pose a liquidity risk in the medium term.
    • The company's geographic and segment exposure is likely concentrated in the domestic Chinese market.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥12,21
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    ¥4.91B
    Net cash
    -¥301.0M
    Current ratio
    5.8
    Debt / equity
    0.1
    ROA
    7.7%
    ROE
    9.8%
    Cash conversion
    152.0%
    CapEx / revenue
    -6.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,72
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    6
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-21 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,72
    Revenueno estimateno estimate2,1B CNY
    Operating incomeno estimateno estimate812,5M CNY
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution6 analysts
    Strong buy0
    Buy2
    Hold3
    Sell1
    Strong sell0
    12-month price target¥16,28 · Median ¥17,75
    Low ¥13,00High ¥18,10
    Operating income · consensus812,5M CNY
    EPS surprise
    −25,9 %
    reported vs consensus · miss
    Revenue surprise
    −12,9 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low¥13,00
    Mean¥16,28
    Median¥17,75
    High¥18,10
    Spot¥12,21
    +33.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin34,9 %Best in class
    Net Margin25,8 %Above P75
    ROE9,8 %Above P75
    Capex / Rev-6,5 %Below median
    D/E0,06Above median
    Cash Conv1,52Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Autek China Inc Market data — financials · 2026-05-26
    • Autek China Inc Market data — analyst estimates · 2026-05-26
    • Autek China Inc Market data — ESG · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    300595.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage